Coeptis Therapeutics (NASDAQ:COEP) Trading Down 2.1% – Here’s What Happened

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) were down 2.1% on Monday . The stock traded as low as $10.85 and last traded at $11.06. Approximately 24,612 shares traded hands during trading, a decline of 48% from the average daily volume of 47,321 shares. The stock had previously closed at $11.30.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Coeptis Therapeutics Price Performance

The firm has a market capitalization of $68.79 million, a price-to-earnings ratio of -3.71 and a beta of -0.48. The stock’s 50-day moving average price is $12.49 and its 200 day moving average price is $14.29. The company has a quick ratio of 4.16, a current ratio of 4.16 and a debt-to-equity ratio of 0.01.

Coeptis Therapeutics (NASDAQ:COEP) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.12) earnings per share (EPS) for the quarter. The business had revenue of $0.86 million for the quarter. Coeptis Therapeutics had a negative net margin of 803.96% and a negative return on equity of 110.89%.

Institutional Investors Weigh In On Coeptis Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP purchased a new position in Coeptis Therapeutics during the fourth quarter worth approximately $259,000. State Street Corp grew its holdings in Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after buying an additional 6,962 shares in the last quarter. Steward Partners Investment Advisory LLC grew its holdings in Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after buying an additional 2,500 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares during the last quarter. Finally, Yorkville Advisors Global LP acquired a new stake in shares of Coeptis Therapeutics in the 3rd quarter worth $140,000. Institutional investors and hedge funds own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.